Interim report May – January 2012/13

  · Order bookings increased 13* percent to SEK 8,080 M (7,186).
  · Net sales increased 11* percent to SEK 6,608 M (5,929).
  · Operating result amounted to SEK 873 M (967) excluding non-recurring items
of SEK -24 M (107).
  · Net income amounted to SEK 504 M (687). Earnings per share amounted to SEK
1.31 (1.83) before dilution and SEK 1.30 (1.81) after dilution. In September
2012 a 4:1 share split was conducted. All data per share has been restated pro
forma.
  · Cash flow after investments was SEK 335 M (372).
  · Exchange rate movements compared to fiscal year 2011/12 are expected to have
a negative impact of approximately three percentage points on growth of net
sales as well as operating profit for the 2012/13 fiscal year.
  · On March 1, Elekta launched Versa HD™ - a new revolutionary linear
accelerator system designed to significantly improve cancer care for the
patients. Featuring high dose delivery and precision beam shaping, Versa HD is
designed for improved treatment optimization and higher efficiency.
  · The outlook has been adjusted due to effects of recent exchange rate
volatility, uncertainty in the US and postponed business in the Middle East.
Based on current market conditions, net sales is expected to increase by
approximately 15 percent in local currency for the 2012/13 fiscal year.
Operating profit is expected to increase by more than 15 percent, excluding
currency effects.

* Compared to last fiscal year based on constant exchange rates.

President and CEO comments
Demand in Elekta’s markets has been favorable so far this fiscal year. In total,
order bookings increased by 13* percent for the first nine months with growth in
all regions. In the third quarter order bookings increased by 6* percent.

The North American market has lately been more cautious, mainly due to
uncertainty about the budget agreement in the US. Elekta’s order bookings was
impacted by a decided but not yet implemented reduction in reimbursement levels
for Medicare patients receiving treatment from Leksell Gamma Knife®. We provide
both linac-based SRS systems and Leksell Gamma Knife® and we remain committed in
our pursuit of the best options and effectiveness in treatment of the patients.

The order trend in the Asia Pacific region was excellent and Elekta has
strengthened its market-leading position. Several countries there are
progressing with structural and long-term expansion of cancer care.

Orders in Europe were overall in line with expectations. The demand scenario is
good in most parts of Europe, where Elekta continues to make solutions available
for qualitative and cost-efficient cancer care for an increasing number of
patients. However, the political uncertainty in the Middle East region resulted
in that business has been postponed.

During a well-attended event in Atlanta, US, we recently launched our new linear
accelerator system, Versa HDTM. It is a revolutionary system that aims to
significantly improve cancer care and quality of life for patients around the
world. Versa HDTMhas a unique combination of high dose rates, exceptional
resolution, speed and low radiation leakage, all key elements for improving
cancer care. The system also offers customized solutions for the major cancer
indications, enabling more patient-specific care. The interest and initial
response from our customers have been very good.

Our long-term development project, aimed at facilitating treatment combined with
advanced magnetic resonance (MR) imaging, continues according to plan. The
University of Texas MD Anderson Cancer Center in Texas, US, recently joined the
consortium of leading clinics contributing to the development of the system
together with Elekta.

Cash flow after investments amounted to SEK 335 M (372) for the period. Cash
conversion amounted to 44 percent for the first nine months. Our aim remains to
achieve cash generation in excess of 70 percent for the fiscal year.

Net sales for the first nine months increased by 11* percent. In the third
quarter net sales was lower compared to the strong comparison quarter last year.
In the third quarter previous year, the newly acquired Nucletron contributed
strongly to net sales, partly due to their fiscal year ended in December and
this effect is estimated to SEK 200 M. We anticipate that in the fourth quarter
we will see strong growth in net sales and have a substantial contribution from
our Brachytherapy business. Operating profit decreased with SEK 94 M to SEK 873
M, excluding non-recurring items. Operating profit was negatively impacted
primarily by the lower net sales from Nucletron, increased investments in R&D as
well as exchange-rate fluctuations that had a negative effect of approximately
SEK 50 M.

We expect a strong fourth quarter. The outlook has been adjusted due to effects
of recent exchange rate volatility, uncertainty in the US and postponed business
in the Middle East. Based on current market conditions, net sales is expected to
increase by approximately 15 percent in local currency for the 2012/13 fiscal
year. Operating profit is expected to increase by more than 15 percent excluding
currency effects.

Exchange rate movements compared to FY 2011/12 are expected to have a negative
impact of approximately three percentage points on growth of net sales as well
as operating profit for the 2012/13 fiscal year.

* Compared to last fiscal year based on constant exchange rates.

Tomas Puusepp
President and CEO

Conference call
Elekta will host a telephone conference at 10:00 – 11:00 CET on March 5, with
President and CEO Tomas Puusepp and CFO Håkan Bergström.
To take part in the conference call, please dial in about 5-10 minutes in
advance and use the access code 927781.
Swedish dial-in number: +46 (0)8 5052 0110, UK dial-in number: +44 (0)20 7162
0077, US dial-in number: + 1 877 491 0064.
The telephone conference will also be broadcasted over the internet (listen
only). Please use the link:
http://webeventservices.reg.meeting-stream.com/73934_elekta

For further information, please contact:

Håkan Bergström, CFO, Elekta AB (publ)
+46 8 587 25 547, hakan.bergstrom@elekta.com

Johan Andersson, Director Investor Relations, Elekta AB (publ)
+46 8 587 25 415, johan.anderssonmelbi@elekta.com

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on March 5, 2013.